|

Axatilimab Clinical Trials

4 actively recruiting trials across 4 locations

▼ -1 trial since May 2026

Also known as: Ab969.g2, Anti-M-CSFR Monoclonal Antibody SNDX-6352, C24H23FN4O3, SNDX 6352, SNDX-6352 +3 more

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 2

Top Sponsors

  • Uma Borate1
  • Stephen Shiao1
  • OHSU Knight Cancer Institute1
  • Dana-Farber Cancer Institute1

Indications

  • Cancer4
  • Breast Cancer2
  • Refractory Myeloproliferative Neoplasm1
  • Recurrent Myeloproliferative Neoplasm1
  • Atypical Chronic Myeloid Leukemia1

Los Angeles, California1 trial

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2

Boston, Massachusetts1 trial

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Beth Israel Deaconess Medical Center

Phase 1

Columbus, Ohio1 trial

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2

Portland, Oregon1 trial

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

OHSU Knight Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.